Cambridge Cognition directors increase holding in company

Cambridge Cognition

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the Company.

The purchases made on the 21st July 2022 are detailed in the table below:

Director/PDMRNo. of Ordinary Shares purchasedPurchase price per Ordinary ShareTotal no. of Ordinary Shares heldPercentage ownership of total issued share capital
Matthew Stork22,950£1.13147,9500.47%
Stephen Symonds22,950£1.1322,9500.07%

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

You might also enjoy reading  Cambridge Cognition wins £2.2 million neurodegenerative disease trial
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

AIM All Share Index